

INPLASY

The Interrelationships Between Cytokines and Schizophrenia: A Systematic review

INPLASY202470128

doi: 10.37766/inplasy2024.7.0128

Received: 31 July 2024

Published: 31 July 2024

Lv, HB; Guo, M; Guo, C; He, KJ.

Corresponding author:

Haibing lv

lv5421213@163.com

Author Affiliation:

Inner Mongolia Minzu University.

ADMINISTRATIVE INFORMATION

Support - The research presented in this paper is supported by the Natural Science Foundations of China (No. 82060256) and the Natural Science Foundation of Inner Mongolia Autonomous Region (No. 2024LHMS08003, No. 2023MS08024).

Review Stage at time of this submission - Completed but not published.

Conflicts of interest - None declared.

INPLASY registration number: INPLASY202470128

Amendments - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 31 July 2024 and was last updated on 31 July 2024.

INTRODUCTION

Review question / Objective In this review, the relationship of CKs with SCZ was examined for understanding the intricate interactions between of the two. Understanding the complex interactions between inflammatory CKs and the central nervous system may provide valuable in-sights into the underlying mechanisms of SCZ, informing innovative therapeutic interventions to restore immune homeostasis and improve outcomes in patients with SCZ.

Condition being studied Schizophrenia (SCZ) imposes a significant burden on patients and their families because of its high prevalence rate and disabling nature. Given the lack of definitive conclusions regarding its path-ogenesis, physicians heavily rely on patients' subjective symptom descriptions for diagnosis because reliable diagnostic biomarkers are currently unavailable.

METHODS

Participant or population Subjects or population study participants included first-episode schizophrenia, refractory schizophrenia, early-stage schizophrenia, chronic schizophrenia, and healthy controls.

Intervention In patients treated with anti-schizophrenia drugs, cytokine levels change after treatment.

Comparator Studies that do not incorporate a comparison group or condition.

Study designs to be included This review will include reviews or experimental articles related to schizophrenia and cytokines.

Eligibility criteria None.

Information sources PubMed database and Google Scholar.

Main outcome(s) This paper summarizes the abnormal expression of cytokines in patients with schizophrenia. Literature searches were conducted within two weeks, and inclusion and exclusion criteria were determined within two days. Literature screening is completed after two weeks, and then summary and paper writing are carried out.

Quality assessment / Risk of bias analysis The included articles were analyzed in relation to schizophrenia and cytokines, excluding articles without abstracts and articles that were only indirectly related to the main focus of the paper.

Strategy of data synthesis After reviewing the results and conclusions in the literature, they are classified and sorted out.

Subgroup analysis None.

Sensitivity analysis None.

Language restriction Select English articles.

Country(ies) involved China.

Keywords schizophrenia; cytokines; biomarkers; extracellular vesicles; research advances.

Contributions of each author

Author 1 - Haibing lv - The first draft was written by Lv Haibing.

Email: lv5421213@163.com

Author 2 - meng Guo - The first draft was written by Meng Guo.

Email: dameng@imun.edu.cn

Author 3 - Chuang Guo - Chuang Guo was responsible for creating graphical representations and refining the initial version of the work.

Email: guochuang@imun.edu.cn

Author 4 - Kuanjun He - Kuanjun He is responsible for the study design and revising and updating the initial draft of the manuscript.